PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 5833: Therapeutic targeting of adhesion receptor GPR56 for the treatment of triple-negative breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYueh-Ming ShyuJJJ. P. JacobCGCarla Godoy

Discussion

Loading...

Member takes

Overview

Demonstrates targeting GPR56 to improve therapeutic options for triple-negative breast cancer, suggesting enhanced treatment efficacy.

Key Points

  • The study aims to evaluate GPR56 as a therapeutic target in triple-negative breast cancer (TNBC) to improve treatment outcomes.
  • Assessed GPR56 expression and its role in TNBC survival pathways.
  • Developed anti-GPR56 antibody-drug conjugates (ADCs) with dual payload delivery mechanisms.
  • Conducted functional studies on TNBC cell lines to evaluate effects of GPR56 modulation.
  • Performed in vitro cytotoxicity tests and in vivo efficacy evaluations using xenografts.
  • GPR56 targeting showed significant cytotoxicity in GPR56-expressing TNBC cell lines.
  • Overexpression of GPR56 enhanced phosphorylation of the FAK-SRC pathway, promoting tumor growth and invasion.
  • The non-agonist anti-GPR56 mAb 9E3 effectively internalized and delivered cytotoxic payloads.
  • 9E3-PBD demonstrated promising in vitro and in vivo anti-tumor efficacy with improved selectivity.

Cite This Study

Shyu et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcfda79560c99a0a2b95https://doi.org/10.1158/1538-7445.am2026-5833
View Full Paper
Ask AI
Bookmark
Share